Triple negative breast cancer (TNBC) is a group of breast cancers which neither express hormonal receptors nor human epidermal growth factor receptor. Hence, there is a lack of currently known targeted therapies and the only available line of systemic treatment option is chemotherapy or more recently immune therapy. However, in patients with relapsed disease after adjuvant or neoadjuvant therapy resistance to chemotherapeutic agents has often developed, which results in poor treatment response. Multidrug resistance has emerged as an important mechanism by which TNBCs mediate drug resistance and occurs primarily due to overexpression of ABC transporter proteins such as P-glycoprotein (Pgp). Pgp overexpression had been linked to poor outcome, reduced survival rates and chemo-resistance in patients. The aim of this mini review is to provide a topical overview of the recent studies and to generate further interest in this critical research area, with an aim to develop an effective and safe approach for overcoming Pgp mediated chemo-resistance in TNBC.

中文翻译：

---

ABCB1 在介导三阴性乳腺癌化疗耐药中的作用。

三阴性乳腺癌（TNBC）是一组既不表达激素受体也不表达人表皮生长因子受体的乳腺癌。因此，目前缺乏已知的靶向治疗，唯一可用的全身治疗选择是化疗或最近的免疫治疗。然而，在辅助或新辅助治疗后疾病复发的患者中，经常会出现对化疗药物的耐药性，导致治疗反应不佳。多药耐药性已成为 TNBC 介导耐药性的重要机制，主要是由于 ABC 转运蛋白如 P-糖蛋白 (Pgp) 的过度表达而发生的。Pgp 过度表达与预后不良、存活率降低和患者的化疗耐药性有关。